ELEVATED LEVELS OF SERUM SECRETONEURIN IN PATIENTS WITH THERAPY RESISTANT CARCINOMA OF THE PROSTATE
Authors:
- 1 April 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 163 (4) , 1161-1165
Abstract
Purpose: The majority of prostate cancers show some degree of neuroendocrine differentiation. It was previously demonstrated that chromogranin A, a constituent of large dense core vesicles of neuro...Keywords
This publication has 22 references indexed in Scilit:
- Serum chromogranin A: Early detection of hormonal resistance in prostate cancer patientsJournal of Clinical Laboratory Analysis, 1998
- Neuroendocrine differentiation in prostatic carcinoma: An updateThe Prostate, 1998
- Presence of chromogranins and regulation of their synthesis and processing in a neuroendocrine prostate tumor cell lineThe Prostate, 1998
- Plasma Chromogranin a in Prostatic Carcinoma and Neuroendocrine TumorsJournal of Urology, 1997
- Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings?The Prostate, 1997
- Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostateUrology, 1996
- Plasma Neuroendocrine Markers in Patients with Benign Prostatic Hyperplasia and Prostatic CarcinomaJournal of Urology, 1996
- Secretogranin II: Molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurinProgress in Neurobiology, 1995
- Do neuroendocrine cells in human prostate cancer express androgen receptor?Histochemistry and Cell Biology, 1993
- Elevated Plasma Chromogranin-A Concentrations in Prostatic CarcinomaJournal of Urology, 1991